Dated disclosed rounds · latest 2024-03-01
Later stage / growth
Mission Therapeutics
Deubiquitylating enzyme (DUB) inhibitor drug discovery
VerifiedSeries DCambridge
- Companies House
- 07630933
- GLEIF LEI
- Not matched
- Latest evidence
- 2024-03-01
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-01
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
3 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series D
£25.2M · 6 named investors
RegistryRegistry fact Company incorporated
MISSION THERAPEUTICS LIMITED · company 07630933
Latest disclosed round
Series D
- Date
- 2024-03-01
- Amount
- GBP 25.2m
- Sector
- Biotech & techbio
- Companies House
- 07630933
- ONS region
- East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
Pfizer Venture InvestmentsleadRoche Venture FundleadSofinnova PartnersleadIP GroupparticipantRosetta CapitalparticipantSR Oneparticipant
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| Pfizer Venture Investments | lead | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Roche Venture Fund | lead | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Sofinnova Partners | lead | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| IP Group | participant | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Rosetta Capital | participant | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| SR One | participant | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
1 disclosed round
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2024-03-01 | Series D | £25.2M | Pfizer Venture Investments · Sofinnova Partners · Roche Venture Fund · SR One · IP Group · Rosetta Capital | Finsmes ↗ · Sofinnovapartners ↗ |
Companies House status and filing snapshot
MISSION THERAPEUTICS LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2011-05-11
- Dissolved
- Not applicable
- Company number
- 07630933
Filing context
- Accounts category
- FULL
- Accounts made up to
- 2024-12-31
- Next accounts due
- 2026-09-30
- Confirmation made up to
- 2026-05-11
- Registry snapshot
- 2026-08-01
- Live check
- Bulk snapshot only
72110Research and experimental development on biotechnology
Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.